{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:08:59Z","timestamp":1794712139652,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shandong Province Taishan Scholar Project","award":["tspd20230608"],"award-info":[{"award-number":["tspd20230608"]}]},{"name":"Shandong Province Taishan Scholar Project","award":["tsqn201909141"],"award-info":[{"award-number":["tsqn201909141"]}]},{"name":"Shandong Provincial Clinical Research Center for Dermatovenerology"},{"name":"Joint Innovation Team for Clinical & Basic Research","award":["202410"],"award-info":[{"award-number":["202410"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40257-025-00925-z","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T03:01:55Z","timestamp":1741575715000},"page":"457-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Outcomes and Prognostic Factors in Bullous Pemphigoid Patients: A 15-Year Review in China"],"prefix":"10.1007","volume":"26","author":[{"given":"Shan","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongda","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Huai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongsheng","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiye","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"issue":"5","key":"925_CR1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.autrev.2017.03.010","volume":"16","author":"IS Ba\u011fc\u0131","year":"2017","unstructured":"Ba\u011fc\u0131 IS, Horv\u00e1th ON, Ruzicka T, S\u00e1rdy M. Bullous pemphigoid. Autoimmun Rev. 2017;16(5):445\u201355. https:\/\/doi.org\/10.1016\/j.autrev.2017.03.010.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"925_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bjd.19022","volume":"184","author":"MSM Persson","year":"2021","unstructured":"Persson MSM, Harman KE, Vinogradova Y, Langan SM, Hippisley-Cox J, Thomas KS, et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998\u20132017: a population-based cohort study. Br J Dermatol. 2021;184(1):68\u201377. https:\/\/doi.org\/10.1111\/bjd.19022.","journal-title":"Br J Dermatol"},{"issue":"2","key":"925_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","volume":"94","author":"D Miyamoto","year":"2019","unstructured":"Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. An Bras Dermatol. 2019;94(2):133\u201346. https:\/\/doi.org\/10.1590\/abd1806-4841.20199007.","journal-title":"An Bras Dermatol"},{"issue":"10","key":"925_CR4","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1111\/jocd.14797","volume":"21","author":"L Lu","year":"2022","unstructured":"Lu L, Chen L, Xu Y, Liu A. Global incidence and prevalence of bullous pemphigoid: A systematic review and meta-analysis. J Cosmet Dermatol. 2022;21(10):4818\u201335. https:\/\/doi.org\/10.1111\/jocd.14797.","journal-title":"J Cosmet Dermatol"},{"issue":"9","key":"925_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00403-017-1778-4","volume":"309","author":"K Thorslund","year":"2017","unstructured":"Thorslund K, Seifert O, Nilz\u00e9n K, Gr\u00f6nhagen C. Incidence of bullous pemphigoid in Sweden 2005\u20132012: a nationwide population-based cohort study of 3761 patients. Arch Dermatol Res. 2017;309(9):721\u20137. https:\/\/doi.org\/10.1007\/s00403-017-1778-4.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"925_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bjd.20743","volume":"186","author":"MSM Persson","year":"2022","unstructured":"Persson MSM, Begum N, Grainge MJ, Harman KE, Grindlay D, Gran S. The global incidence of bullous pemphigoid: a systematic review and meta-analysis. Br J Dermatol. 2022;186(3):414\u201325. https:\/\/doi.org\/10.1111\/bjd.20743.","journal-title":"Br J Dermatol"},{"issue":"2","key":"925_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/ajd.13822","volume":"63","author":"JG Chung","year":"2022","unstructured":"Chung JG, Ramji R, Coomarasamy C, Jarrett P, Rademaker M, Patel DC. Bullous pemphigoid: Its incidence, mortality and clinical outcome in New Zealand. Australas J Dermatol. 2022;63(2):197\u2013203. https:\/\/doi.org\/10.1111\/ajd.13822.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"925_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/bjd\/ljad432","volume":"190","author":"JA Fairley","year":"2024","unstructured":"Fairley JA, Messingham KAN. Omalizumab therapy of bullous pemphigoid. Br J Dermatol. 2024;190(2):142\u20133. https:\/\/doi.org\/10.1093\/bjd\/ljad432.","journal-title":"Br J Dermatol"},{"issue":"9","key":"925_CR9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","volume":"159","author":"L Zhao","year":"2023","unstructured":"Zhao L, Wang Q, Liang G, Zhou Y, Yiu N, Yang B, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol. 2023;159(9):953\u201360. https:\/\/doi.org\/10.1001\/jamadermatol.2023.2428.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"925_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","volume":"25","author":"M Karakioulaki","year":"2024","unstructured":"Karakioulaki M, Eyerich K, Patsatsi A. Advancements in bullous pemphigoid treatment: a comprehensive pipeline update. Am J Clin Dermatol. 2024;25(2):195\u2013212. https:\/\/doi.org\/10.1007\/s40257-023-00832-1.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"925_CR11","doi-asserted-by":"publisher","first-page":"Cd002292","DOI":"10.1002\/14651858.CD002292.pub3","volume":"2010","author":"G Kirtschig","year":"2010","unstructured":"Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;2010(10):Cd002292. https:\/\/doi.org\/10.1002\/14651858.CD002292.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"925_CR12","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1111\/jdv.18441","volume":"36","author":"F Bardazzi","year":"2022","unstructured":"Bardazzi F, Filippi F, Chessa MA, Iommi M, Loi C, Campanati A, et al. Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study. J Eur Acad Dermatol Venereol. 2022;36(12):2473\u201381. https:\/\/doi.org\/10.1111\/jdv.18441.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"925_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2340\/00015555-2930","volume":"99","author":"K Kridin","year":"2019","unstructured":"Kridin K, Shihade W, Bergman R. Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol. 2019;99(1):72\u20137. https:\/\/doi.org\/10.2340\/00015555-2930.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"925_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/07853890.2018.1443346","volume":"50","author":"Y Wang","year":"2018","unstructured":"Wang Y, Mao X, Wang Y, Zeng Y, Liu Y, Jin H, et al. Relapse of bullous pemphigoid: an update on this stubborn clinical problem. Ann Med. 2018;50(3):234\u20139. https:\/\/doi.org\/10.1080\/07853890.2018.1443346.","journal-title":"Ann Med"},{"issue":"1","key":"925_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamadermatol.2013.5757","volume":"150","author":"F Fichel","year":"2014","unstructured":"Fichel F, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, et al. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol. 2014;150(1):25\u201333. https:\/\/doi.org\/10.1001\/jamadermatol.2013.5757.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"925_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00403-017-1772-x","volume":"309","author":"A Kalinska-Bienias","year":"2017","unstructured":"Kalinska-Bienias A, Lukowska-Smorawska K, Jagielski P, Kowalewski C, Wozniak K. Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland. Arch Dermatol Res. 2017;309(9):709\u201319. https:\/\/doi.org\/10.1007\/s00403-017-1772-x.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"925_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1684\/ejd.2012.1906","volume":"23","author":"LM Zhang","year":"2013","unstructured":"Zhang LM, Wu J, Xiao T, Jin GY, Li JH, Geng L, et al. Treatment and mortality rate of bullous pemphigoid in China: a hospital-based study. Eur J Dermatol. 2013;23(1):94\u20138. https:\/\/doi.org\/10.1684\/ejd.2012.1906.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"925_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/archdermatol.2012.2994","volume":"149","author":"J Li","year":"2013","unstructured":"Li J, Zuo YG, Zheng HY. Mortality of bullous pemphigoid in China. JAMA Dermatol. 2013;149(1):106\u20138. https:\/\/doi.org\/10.1001\/archdermatol.2012.2994.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"925_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","volume":"83","author":"R Abdat","year":"2020","unstructured":"Abdat R, Waldman RA, de Bedout V, Czernik A, Mcleod M, King B, et al. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. J Am Acad Dermatol. 2020;83(1):46\u201352. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.089.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"925_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ajd.13852","volume":"63","author":"H Titou","year":"2022","unstructured":"Titou H, Hjira N. Mortality and prognostic factors of Bullous Pemphigoid in a Moroccan population. Australas J Dermatol. 2022;63(3):328\u201334. https:\/\/doi.org\/10.1111\/ajd.13852.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"925_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15095","volume":"33","author":"N Amonchaisakda","year":"2024","unstructured":"Amonchaisakda N, Rujitharanawong C, Tuchinda P, Kulthanan K, Chularojanamontri L. Hospitalization and mortality in Asian autoimmune bullous dermatosis patients: A 17-year retrospective study. Exp Dermatol. 2024;33(5): e15095. https:\/\/doi.org\/10.1111\/exd.15095.","journal-title":"Exp Dermatol"},{"issue":"3","key":"925_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s44197-024-00277-7","volume":"14","author":"Z Chen","year":"2024","unstructured":"Chen Z, Wang L, Ma L, Yang F, Chen S, Yang J, et al. Epidemiological insights into autoimmune bullous diseases in China: a comprehensive analysis. J Epidemiol Glob Health. 2024;14(3):513\u201323. https:\/\/doi.org\/10.1007\/s44197-024-00277-7.","journal-title":"J Epidemiol Glob Health."},{"issue":"4","key":"925_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","volume":"18","author":"P Bernard","year":"2017","unstructured":"Bernard P, Antonicelli F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol. 2017;18(4):513\u201328. https:\/\/doi.org\/10.1007\/s40257-017-0264-2.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"925_CR24","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/bjd.17591","volume":"180","author":"I Ujiie","year":"2019","unstructured":"Ujiie I, Ujiie H, Iwata H, Shimizu H. Clinical and immunological features of pemphigus relapse. Br J Dermatol. 2019;180(6):1498\u2013505. https:\/\/doi.org\/10.1111\/bjd.17591.","journal-title":"Br J Dermatol"},{"issue":"3","key":"925_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","volume":"66","author":"DF Murrell","year":"2012","unstructured":"Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2011.06.032.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"925_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","volume":"72","author":"DF Murrell","year":"2015","unstructured":"Murrell DF, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K, et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol. 2015;72(1):168\u201374. https:\/\/doi.org\/10.1016\/j.jaad.2014.08.024.","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"925_CR27","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0713.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"925_CR28","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","volume":"132","author":"P Joly","year":"2012","unstructured":"Joly P, Baricault S, Sparsa A, Bernard P, B\u00e9dane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132(8):1998\u20132004. https:\/\/doi.org\/10.1038\/jid.2012.35.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"925_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/ajd.13458","volume":"62","author":"LC Heng","year":"2021","unstructured":"Heng LC, Phoon YW, Pang SM, Lee HY. Pemphigoid and pemphigus: Comparative analysis of clinical epidemiology, course and outcome in an Asian Academic Medical Centre. Australas J Dermatol. 2021;62(2):288\u201390. https:\/\/doi.org\/10.1111\/ajd.13458.","journal-title":"Australas J Dermatol"},{"issue":"7","key":"925_CR30","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1111\/jdv.16363","volume":"34","author":"B Monshi","year":"2020","unstructured":"Monshi B, Gulz L, Piringer B, Wiala A, Kivaranovic D, Schmidt M, et al. Anti-BP180 autoantibody levels at diagnosis correlate with 1-year mortality rates in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2020;34(7):1583\u20139. https:\/\/doi.org\/10.1111\/jdv.16363.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"925_CR31","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1177\/12034754221088562","volume":"26","author":"P Cyr","year":"2022","unstructured":"Cyr P, Lim D, Caruana M, Pennou C, Lemieux A, Fortin B, et al. Bullous pemphigoid-associated mortality rate in a Canadian tertiary referral centre. J Cutan Med Surg. 2022;26(4):386\u201392. https:\/\/doi.org\/10.1177\/12034754221088562.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"925_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamadermatol.2021.5125","volume":"158","author":"WC Shen","year":"2022","unstructured":"Shen WC, Chiang HY, Chen PS, Lin YT, Kuo CC, Wu PY. Risk of all-cause mortality, cardiovascular disease mortality, and cancer mortality in patients with bullous pemphigoid. JAMA Dermatol. 2022;158(2):167\u201375. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5125.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"925_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5021\/ad.2018.30.1.13","volume":"30","author":"HW Jeon","year":"2018","unstructured":"Jeon HW, Yun SJ, Lee SC, Won YH, Lee JB. Mortality and comorbidity profiles of patients with bullous pemphigoid in Korea. Ann Dermatol. 2018;30(1):13\u20139. https:\/\/doi.org\/10.5021\/ad.2018.30.1.13.","journal-title":"Ann Dermatol"},{"issue":"4","key":"925_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/jdv.12065","volume":"28","author":"A Gual","year":"2014","unstructured":"Gual A, Mascar\u00f3 JM Jr, Rojas-Farreras S, Guilabert A, Juli\u00e0 M, Iranzo P. Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre. J Eur Acad Dermatol Venereol. 2014;28(4):500\u20136. https:\/\/doi.org\/10.1111\/jdv.12065.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"925_CR35","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/ijd.12492","volume":"53","author":"AB Serwin","year":"2014","unstructured":"Serwin AB, Musialkowska E, Piascik M. Incidence and mortality of bullous pemphigoid in north-east Poland (Podlaskie Province), 1999\u20132012: a retrospective bicentric cohort study. Int J Dermatol. 2014;53(10):432\u20137. https:\/\/doi.org\/10.1111\/ijd.12492.","journal-title":"Int J Dermatol"},{"issue":"11","key":"925_CR36","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/ijd.12619","volume":"54","author":"M Banihashemi","year":"2015","unstructured":"Banihashemi M, Zabolinejad N, Vahabi S, Razavi HS. Survey of bullous pemphigoid disease in northern Iran. Int J Dermatol. 2015;54(11):1246\u20139. https:\/\/doi.org\/10.1111\/ijd.12619.","journal-title":"Int J Dermatol"},{"issue":"6","key":"925_CR37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.2340\/00015555-2347","volume":"96","author":"AK F\u00f6rsti","year":"2016","unstructured":"F\u00f6rsti AK, Jokelainen J, Timonen M, Tasanen K. Risk of death in bullous pemphigoid: a retrospective database study in Finland. Acta Derm Venereol. 2016;96(6):758\u201361. https:\/\/doi.org\/10.2340\/00015555-2347.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"925_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00403-018-1875-z","volume":"311","author":"M Rozenblat","year":"2019","unstructured":"Rozenblat M, Halaj A, Rozenblat T, Fisher S, Sah M, Dodiuk-Gad RP, et al. Mortality and risk factors among Israeli bullous pemphigoid patients. Arch Dermatol Res. 2019;311(1):19\u201327. https:\/\/doi.org\/10.1007\/s00403-018-1875-z.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"925_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","volume":"71","author":"KE Brick","year":"2014","unstructured":"Brick KE, Weaver CH, Lohse CM, Pittelkow MR, Lehman JS, Camilleri MJ, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014;71(1):92\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2014.02.030.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"925_CR40","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/j.0022-202X.2004.22504.x","volume":"122","author":"RL Colbert","year":"2004","unstructured":"Colbert RL, Allen DM, East.wood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol. 2004;122(5):1091\u20135. https:\/\/doi.org\/10.1111\/j.0022-202X.2004.22504.x.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"925_CR41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.det.2011.06.012","volume":"29","author":"M Eskin-Schwartz","year":"2011","unstructured":"Eskin-Schwartz M, David M, Mimouni D. Mycophenolate mofetil for the management of autoimmune bullous diseases. Dermatol Clin. 2011;29(4):555\u20139. https:\/\/doi.org\/10.1016\/j.det.2011.06.012.","journal-title":"Dermatol Clin"},{"issue":"1","key":"925_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clindermatol.2011.03.013","volume":"30","author":"M Meurer","year":"2012","unstructured":"Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol. 2012;30(1):78\u201383. https:\/\/doi.org\/10.1016\/j.clindermatol.2011.03.013.","journal-title":"Clin Dermatol"},{"issue":"2","key":"925_CR43","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1159\/000516632","volume":"238","author":"CY Wu","year":"2022","unstructured":"Wu CY, Wu CY, Li CP, Lin YH, Chang YT. Association of immunosuppressants with mortality of patients with bullous pemphigoid: a nationwide population-based cohort study. Dermatology. 2022;238(2):378\u201385. https:\/\/doi.org\/10.1159\/000516632.","journal-title":"Dermatology"},{"issue":"11","key":"925_CR44","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/exd.13779","volume":"27","author":"K Tanita","year":"2018","unstructured":"Tanita K, Fujimura T, Sato Y, Lyu C, Aiba S. Minocycline decreases Th2 chemokines from M2 macrophages: Possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs. Exp Dermatol. 2018;27(11):1268\u201372. https:\/\/doi.org\/10.1111\/exd.13779.","journal-title":"Exp Dermatol"},{"issue":"6","key":"925_CR45","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","volume":"130","author":"DP Fivenson","year":"1994","unstructured":"Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130(6):753\u20138.","journal-title":"Arch Dermatol"},{"issue":"6","key":"925_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13861","volume":"33","author":"S Salman","year":"2020","unstructured":"Salman S, Awad M, Sarsik S, Ibrahim AM, Fathi M, Agha NY, et al. Treatment options for autoimmune bullous dermatoses other than systemic steroids: A systematic review and network meta-analysis. Dermatol Ther. 2020;33(6): e13861. https:\/\/doi.org\/10.1111\/dth.13861.","journal-title":"Dermatol Ther"},{"key":"925_CR47","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","volume":"167","author":"R della Torre","year":"2012","unstructured":"della Torre R, Combescure C, Cortes B, Marazza G, Beltraminelli H, Naldi L, et al. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol. 2012;167:1111\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11108.x.","journal-title":"Br J Dermatol"},{"issue":"7","key":"925_CR48","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/1346-8138.13782","volume":"44","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Luo Y, Han Y, Tian R, Li W, Yao X. Non-bullous lesions as the first manifestation of bullous pemphigoid: A retrospective analysis of 181 cases. J Dermatol. 2017;44(7):742\u20136. https:\/\/doi.org\/10.1111\/1346-8138.13782.","journal-title":"J Dermatol"},{"issue":"5","key":"925_CR49","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaad.2017.10.035","volume":"78","author":"A Lamberts","year":"2018","unstructured":"Lamberts A, Meijer JM, Jonkman MF. Nonbullous pemphigoid: a systematic review. J Am Acad Dermatol. 2018;78(5):989-995.e2. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.035.","journal-title":"J Am Acad Dermatol"},{"key":"925_CR50","unstructured":"Statistical Bulletin on the Development of China's Health Undertakings in 2023. https:\/\/www.gov.cn\/lianbo\/bumen\/202408\/content_6971241.htm. Accessed 10 Sep 2024."},{"key":"925_CR51","unstructured":"Global Burden of Disease (GBD) data. https:\/\/vizhub.healthdata.org\/gbd-results\/. Accessed 10 Sep 2024."},{"issue":"5","key":"925_CR52","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.annder.2009.01.009","volume":"136","author":"V Doffoel-Hantz","year":"2009","unstructured":"Doffoel-Hantz V, Sparsa A, Marin B, Durox H, Bonnetblanc JM, B\u00e9dane C. One year follow-up of patients with bullous pemphigoid. Ann Dermatol Venereol. 2009;136(5):407\u201311. https:\/\/doi.org\/10.1016\/j.annder.2009.01.009.","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"925_CR53","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/bjd\/ljad369","volume":"190","author":"R Chebani","year":"2024","unstructured":"Chebani R, Lombart F, Chaby G, Dadban A, Debarbieux S, Viguier MA, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol. 2024;190(2):258\u201365. https:\/\/doi.org\/10.1093\/bjd\/ljad369.","journal-title":"Br J Dermatol"},{"key":"925_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.680871","volume":"8","author":"X Chen","year":"2021","unstructured":"Chen X, Zhao W, Jin H, Li L. Risk factors for mucosal involvement in bullous pemphigoid and the possible mechanism: a review. Front Med (Lausanne). 2021;8: 680871. https:\/\/doi.org\/10.3389\/fmed.2021.680871.","journal-title":"Front Med (Lausanne)."},{"issue":"2","key":"925_CR55","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/jamadermatol.2018.5049","volume":"155","author":"K Kridin","year":"2019","unstructured":"Kridin K, Bergman R. Assessment of the prevalence of mucosal involvement in bullous pemphigoid. JAMA Dermatol. 2019;155(2):166\u201371. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5049.","journal-title":"JAMA Dermatol"},{"key":"925_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fmed.2018.00139","volume":"5","author":"H Koga","year":"2018","unstructured":"Koga H, Teye K, Ishii N, Ohata C, Nakama T. High index values of enzyme-linked immunosorbent assay for BP180 at baseline predict relapse in patients with bullous pemphigoid. Front Med (Lausanne). 2018;5:139. https:\/\/doi.org\/10.3389\/fmed.2018.00139.","journal-title":"Front Med (Lausanne)."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00925-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00925-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00925-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T07:56:53Z","timestamp":1747468613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00925-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00925-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"20 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded in part through the Shandong Province Taishan Scholar Project (tspd20230608 and tsqn201909141), the Shandong Provincial Clinical Research Center for Dermatovenerology, and Joint Innovation Team for Clinical & Basic Research (202410).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors have completed the ICMJE uniform disclosure form and no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest\/Competing Interests"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board at the Shandong Provincial Institute of Dermatology and Venereology (No. 20221223KYKTKS001).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Verbal informed consent was obtained prior to the interview.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Verbal informed consent was obtained prior to the interview.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. Data are located in controlled access data storage at Hospital for Skin Diseases, Shandong First Medical University.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data And Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"HL, and FRZ conceived the work. SC, PCH, HDL,\u00a0TSC, and PYX followed the patients and contributed to data collection. WCL, SC and ZZW performed the statistical analyses. YXL, GZZ, and SLC performed pathology studies. BQY, YHS, QY, MW, ZXS, TSC, HL, and FRZ performed clinical studies. SC, WCL, ZZW and HL wrote and revised the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. Finally, all authors critically revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}